Last reviewed · How we verify
Topical timolol maleate
Topical timolol maleate is a Beta-adrenergic antagonist Small molecule drug developed by Unity Health Toronto. It is currently FDA-approved for Glaucoma, Ocular hypertension. Also known as: Topical timolol maleate 0.5% drops, timolol, beta blocker, Timoptic.
Topical timolol maleate is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.
Topical timolol maleate is a small molecule that acts as a beta-1 adrenergic receptor antagonist. It is used to treat various eye conditions, including glaucoma and ocular hypertension, as well as other conditions such as acne vulgaris, erythema, post-inflammatory erythema, and scleral buckling.
At a glance
| Generic name | Topical timolol maleate |
|---|---|
| Also known as | Topical timolol maleate 0.5% drops, timolol, beta blocker, Timoptic |
| Sponsor | Unity Health Toronto |
| Drug class | Beta-adrenergic antagonist |
| Target | Beta-1 and beta-2 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Timolol blocks beta-1 and beta-2 adrenergic receptors in the ciliary body of the eye, which reduces the rate of aqueous humor secretion. This leads to a decrease in intraocular pressure, making it effective for conditions characterized by elevated eye pressure. The topical formulation allows direct delivery to ocular tissues while minimizing systemic absorption.
Approved indications
- Glaucoma
- Ocular hypertension
Common side effects
- Ocular irritation or discomfort
- Blurred vision
- Conjunctivitis
- Systemic beta-blockade effects (bradycardia, bronchospasm in susceptible patients)
Key clinical trials
- Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris (EARLY_PHASE1)
- Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas (PHASE4)
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
- Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing (PHASE2)
- Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension (PHASE2)
- Topical Timolol Benefit in Venous Ulcers (PHASE2)
- Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical timolol maleate CI brief — competitive landscape report
- Topical timolol maleate updates RSS · CI watch RSS
- Unity Health Toronto portfolio CI
Frequently asked questions about Topical timolol maleate
What is Topical timolol maleate?
How does Topical timolol maleate work?
What is Topical timolol maleate used for?
Who makes Topical timolol maleate?
Is Topical timolol maleate also known as anything else?
What drug class is Topical timolol maleate in?
What development phase is Topical timolol maleate in?
What are the side effects of Topical timolol maleate?
What does Topical timolol maleate target?
Related
- Drug class: All Beta-adrenergic antagonist drugs
- Target: All drugs targeting Beta-1 and beta-2 adrenergic receptors
- Manufacturer: Unity Health Toronto — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Glaucoma
- Indication: Drugs for Ocular hypertension
- Also known as: Topical timolol maleate 0.5% drops, timolol, beta blocker, Timoptic
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing